Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
146.82
+0.18 (0.12%)
At close: Jan 24, 2025, 4:00 PM
146.99
+0.17 (0.12%)
After-hours: Jan 24, 2025, 7:18 PM EST
Johnson & Johnson Revenue
In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth. Johnson & Johnson had revenue of $22.52B in the quarter ending December 29, 2024, with 5.26% growth.
Revenue (ttm)
$88.82B
Revenue Growth
+4.30%
P/S Ratio
4.02
Revenue / Employee
$673,397
Employees
131,900
Market Cap
353.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.95B |
| Eli Lilly and Company | 40.86B |
JNJ News
- 1 day ago - Best 5 dividend aristocrat stocks to buy and hold - Invezz
- 2 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Johnson & Johnson (JNJ) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 2 days ago - What's Next For JNJ Stock After An Upbeat Q4? - Forbes
- 3 days ago - Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst - Benzinga
- 3 days ago - Johnson & Johnson (JNJ) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 3 days ago - Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology - PRNewsWire
- 4 days ago - Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings - Fast Company
- 4 days ago - Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing - Seeking Alpha